Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

NCT04097769 is registered in ClinicalTrials.gov with Waterstone Hanxbio Pty Ltd as lead sponsor.

NCT NCT04097769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04097769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, First-in-Human Study Evaluating the Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
Lead sponsor
Waterstone Hanxbio Pty Ltd
Phase
Phase 1
Overall status
Completed
Start date
June 12, 2019
Completion date
September 29, 2022
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor